Table 1.
Descriptive characteristics of study cohort
| Characteristic | |
|---|---|
| Total number of patients analyzed | 29 |
| Female, N (%) | 7 (24.1) |
| Median age (y) at diagnosis with EoE (IQR) | 13.2 (6.4) |
| Median age (y) at study enrollment (IQR) | 14.1 (4.6) |
| Features of GC therapy | |
| Duration of GC therapy (days ± SD) | 104.6 ± 23.7 |
| Oral viscous budesonide, N (%) | 26 (89.7) |
| Swallowed fluticasone, N (%) | 3 (10.3) |
| Concomitant conditions, N (%) | |
| Asthma | 21 (72.4) |
| Allergiesa | 27 (93.1) |
| Eczema | 10 (34.5) |
| Additional forms of GC therapy, by patient, N (%) | |
| Total number of patients receiving additional forms | 13 (44.8 %) |
| Inhaled corticosteroidsb | 11 (37.9 %) |
| Intranasal | 1 (3.4 %) |
| Topical | 2 (6.9 %) |
EoE eosinophilic esophagitis, ICS inhaled corticosteroids, IQR interquartile range, GC glucocorticoid, N number, SD standard deviation, y years
aA diagnosis of allergy was made based on skin prick testing for food and/or environmental allergies by an allergist
bMost participants had a history of infrequent ICS use during inter-current infection only. Two participants were being actively treated with daily moderate ICS doses (Flovent 250 mcg daily and Alvesco 400 mcg daily)